|
Incidence of gastrointestinal adverse events occurring in ≥ 10% of patients during the two year treatment period |
||
| Percentage of patients with event |
||
|
|
||
| Clodronate (n = 530) |
Placebo (n = 539) |
|
|
|
||
| Nausea |
27.0 |
29.8 |
| Diarrhoea1 |
19.9 |
10.0 |
| Dyspepsia |
15.6 |
13.3 |
| Vomiting |
14.7 |
13.1 |
| Abdominal pain |
13.6 |
10.5 |
| Constipation |
12.5 |
12.2 |
| Stomatitis |
8.4 |
10.2 |
|
1P < 0.05 versus placebo. | ||
Powles et al. Breast Cancer Research 2006 8:R13 doi:10.1186/bcr1384 |
||